224 related articles for article (PubMed ID: 27739435)
1. Identification of recurrent mutational events in anorectal melanoma.
Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA
Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Roles of
Wróblewska JP; Dias-Santagata D; Ustaszewski A; Wu CL; Fujimoto M; Selim MA; Biernat W; Ryś J; Marszalek A; Hoang MP
Cells; 2021 Aug; 10(9):. PubMed ID: 34571863
[TBL] [Abstract][Full Text] [Related]
4. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP
BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999
[TBL] [Abstract][Full Text] [Related]
5. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.
Schaefer T; Satzger I; Gutzmer R
Medicine (Baltimore); 2017 Jan; 96(1):e5753. PubMed ID: 28072717
[TBL] [Abstract][Full Text] [Related]
6. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
Wroblewska JP; Mull J; Wu CL; Fujimoto M; Ogawa T; Marszalek A; Hoang MP
Am J Surg Pathol; 2019 Feb; 43(2):168-177. PubMed ID: 30273197
[TBL] [Abstract][Full Text] [Related]
7. Anorectal Melanoma - a Histopathological Case Report and a Review of the Literature.
Kobakova I; Stoyanov G; Popov H; Spasova-Nyagulova S; Stefanova N; Stoev L; Yanulova N
Folia Med (Plovdiv); 2018 Dec; 60(4):641-646. PubMed ID: 31188769
[TBL] [Abstract][Full Text] [Related]
8. c-kit gene mutation and CD117 expression in human anorectal melanomas.
Ni S; Huang D; Chen X; Huang J; Kong Y; Xu Y; Du X; Sheng W
Hum Pathol; 2012 Jun; 43(6):801-7. PubMed ID: 22154054
[TBL] [Abstract][Full Text] [Related]
9. KIT genetic alterations in anorectal melanomas.
Santi R; Simi L; Fucci R; Paglierani M; Pepi M; Pinzani P; Merelli B; Santucci M; Botti G; Urso C; Massi D
J Clin Pathol; 2015 Feb; 68(2):130-4. PubMed ID: 25398993
[TBL] [Abstract][Full Text] [Related]
10. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
Itoh M; Goto A; Wakasugi H; Yoshida Y; Matsunaga Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Arimura Y; Shinomura Y
Int J Clin Oncol; 2011 Aug; 16(4):428-34. PubMed ID: 21069551
[TBL] [Abstract][Full Text] [Related]
11. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.
Helmke BM; Mollenhauer J; Herold-Mende C; Benner A; Thome M; Gassler N; Wahl W; Lyer S; Poustka A; Otto HF; Deichmann M
Gastroenterology; 2004 Dec; 127(6):1815-20. PubMed ID: 15578519
[TBL] [Abstract][Full Text] [Related]
13. NF1 mutations in conjunctival melanoma.
Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
[TBL] [Abstract][Full Text] [Related]
14. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
[TBL] [Abstract][Full Text] [Related]
15. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
16. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
17. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
18. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
[TBL] [Abstract][Full Text] [Related]
19. Whole-genome landscapes of major melanoma subtypes.
Hayward NK; Wilmott JS; Waddell N; Johansson PA; Field MA; Nones K; Patch AM; Kakavand H; Alexandrov LB; Burke H; Jakrot V; Kazakoff S; Holmes O; Leonard C; Sabarinathan R; Mularoni L; Wood S; Xu Q; Waddell N; Tembe V; Pupo GM; De Paoli-Iseppi R; Vilain RE; Shang P; Lau LMS; Dagg RA; Schramm SJ; Pritchard A; Dutton-Regester K; Newell F; Fitzgerald A; Shang CA; Grimmond SM; Pickett HA; Yang JY; Stretch JR; Behren A; Kefford RF; Hersey P; Long GV; Cebon J; Shackleton M; Spillane AJ; Saw RPM; López-Bigas N; Pearson JV; Thompson JF; Scolyer RA; Mann GJ
Nature; 2017 May; 545(7653):175-180. PubMed ID: 28467829
[TBL] [Abstract][Full Text] [Related]
20. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
